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Sir,
We appreciate the interest of Lassus and Butzow in our report
on the prognostic value of p53 immunostaining in epithelial
ovarian cancer. In this study, we performed statistical analysis
using two cutoff methods for aberrant p53 expression as
determined by immunohistochemistry: the conventional classifi-
cation, in which tumour samples showing 450% moderate or
strong staining are considered to show aberrant expression and
the new classification as proposed by Lassus et al (2003) in which
tumours showing completely negative, 450% moderate and
strongly positive staining are considered to show aberrant p53
staining (Lassus et al, 2003).
We agree that immunohistochemical staining can be interpreted
in different ways that may have varying success in accurately
classifying the samples in biologically meaningful groups. One of
the main issues raised in the letter is that further research on the
prognostic value of completely negative p53 immunostaining
should be undertaken. This was indeed one of the main reasons
we also included analysis of the scoring system as proposed by
Lassus et al (2003) in this large independent sample set. For
reasons of clarity and conciseness, we did not extensively present
results of data analysis for both classifications in the paper
(de Graeff et al, 2006). We chose to present mainly on the
conventional p53 classification because this was our original
hypothesis and we centred our results on the original questions
proposed, as we did not wish to bias the reporting on the basis of
the study results. However, we will now take the opportunity to
present these data.
Although we agree that it may be challenging to find molecular
prognostic markers with prognostic capabilities stronger than
some clinical factors, we argue that it is vital to put molecular
markers into a clinical context using multivariate analysis to
determine their potential utility. Multivariate analysis using the
‘Lassus’ classification showed that aberrant p53 immunostaining
was a significant predictor of poor overall survival (n¼222; HR
1.7, P¼0.035). However, making some allowance for multiple
testing would means that the P-value of 0.035 for p53 immuno-
staining is of borderline statistical significance. More crucially, the
results of univariate analysis described below yielded markedly
inconsistent results across the Dutch and Scottish cohort, raising
real questions around the reliability of negative p53 immuno-
staining as a prognostic factor.
Statistical analysis for the Dutch and Scottish cohort separately
using the ‘Lassus’ classification showed that the proportion of
tumours staining completely negative was comparable across the
two patient groups (26.8% in the Scottish group and 27.1% in the
Dutch group). Kaplan–Meier survival analysis for progression free
and overall survival showed that while strongly positive p53
immunostaining was associated with poor survival in both cohorts,
the value of completely negative staining was less clear. In
univariate Cox regression analysis for the Dutch cohort (n¼188),
completely negative immunostaining was strongly associated with
poor PFS and OS (HR 2.5; 95%CI 1.4–4.4; P¼0.002 and HR 3.1;
95%CI 1.7–5.4; Po0.001, respectively). In contrast, in the Scottish
group (n¼328) completely negative staining did not predict PFS
or OS (HR 0.87; 95%CI 0.6–1.2; P¼0.50 and HR 0.89; 95%CI 0.6–
1.3; P¼0.89, respectively). Restricting the analysis to serous
carcinomas only did not influence the outcome of statistical
analysis.
One possible explanation for contrasting results of statistical
analysis, regarding completely negative p53 immunostaining, is
that in addition to alterations at the gene, transcriptional or
translational level, completely negative immunostaining could also
result from time-dependent lack of antigen preservation in
formalin-fixed, paraffin-embedded tissues (Prioleau and Schnitt,
1995). Even with minimal methodological variability between the
two cohorts, we could not correct for differences in tissue storage
and handling. For their study, Lassus et al (2003) included tumour
tissues collected from 1964 to 2002. It is very likely that at least
part of the older tumour samples used in their study stained
completely negative as a result of p53 antigen loss. Mutational
analysis or assessment of antigen damage by immunohistohemical
control stainings (Battifora, 1991) could aid in selecting tumours
that show completely negative staining resulting from mutations or
alterations at the transcriptional or translational level. Published online 17 April 2007
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www.bjcancer.comIn summary, although results of statistical analysis showed that
aberrant p53 staining using the classification as proposed by Lassus
et al (2003) is a potential significant predictor of overall survival in
multivariate analysis, these findings should be interpreted with
caution. Definitive, reliable evidence for the possible prognostic
value of (completely negative) p53 staining in ovarian cancer
should be obtained from clinical trials with clearly defined
inclusion criteria and methodological standardisation.
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